Novo Nordisk has secured approval from the U.S. Food and Drug Administration (FDA) to market its oral GLP-1 medication, Rybelsus, specifically aimed at reducing the risk...
A recent study from the University of Utah explores innovative approaches to enhancing GLP-1 agonists, potentially paving the way for a new generation of anti-obesity medications....
